Search the Newsreel

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Advances differentiated immunology program with the potential to address significant unmet need in immune-mediated disease Novel in vivo CAR-T platform is designed to generate CAR-T therapies directly within the body, enabling scalable treatments with durable, disease-modifying, and curative potential Strengthens Johnson & Johnson's leadership …

Explainer-Can J&J finally put the talc litigation behind it?

By Dietrich Knauth NEW YORK, July 29 (Reuters) - After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that could finally help …

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

This article compares the revenue growth strategies of Johnson & Johnson (JNJ) and Eli Lilly (LLY). While J&J offers reliable stability with slower, steady growth, Eli Lilly shows rapid revenue expansion, primarily driven by its diabetes and obesity drugs. Investors are advised to watch …

Johnson and Johnson Offers $5 Billion to Settle Tens of Thousands of Talc Lawsuits

What Johnson & Johnson Stock Told You Before It Surged

Photo by kravaivan11 on Pixabay Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved. A Run That Matched Merck And More Than Tripled The S&P Over the year from late July 2025, Johnson …

Johnson & Johnson lawsuit: J&J offers up to $5.5 billion to settle baby powder ovarian cancer suits

Johnson & Johnson has proposed a settlement of up to $5.5 billion to resolve approximately 76,000 U.S. lawsuits alleging that its talcum powder products caused ovarian cancer. The company maintains that the lawsuits lack scientific merit and that the settlement aims to bring closure …

Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight

Johnson & Johnson has offered a $5.5 billion settlement to resolve ongoing lawsuits alleging its talc products caused ovarian cancer. This proposal comes after a previous $9 billion settlement from a subsidiary was denied by a bankruptcy court judge. The company aims to put …

Jim Cramer: J&J talc settlement is good for a stock that has so much going for it already

Jim Cramer highlighted Johnson & Johnson's talc settlement as a positive development, helping to boost the stock to new highs. However, he emphasized that more compelling reasons exist to own J&J, such as its strong pharmaceutical and medical technology portfolio. The company's impressive drug …

Johnson & Johnson (JNJ) Stock May Be 31% Undervalued As Myeloma Trial Results Impress

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Johnson & Johnson stock has delivered a 77.7% total return over the past five …

Johnson & Johnson agrees to pay $5.5 billion in talc powder settlement

Johnson & Johnson has agreed to a $5.5 billion settlement for lawsuits alleging its talc products caused ovarian cancer. This settlement is contingent on the participation of remaining claimants and follows a previous denial of a larger $9 billion settlement by a bankruptcy judge …

Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation

Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation Proactive uses images sourced from Shutterstock Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that its talc-based products, including its baby powder, …

Cramer’s Mad Dash: Johnson & Johnson

Jim Cramer delivers his daily "Mad Dash" segment focusing on Johnson & Johnson. The article features a video clip of Cramer discussing the company, with the segment lasting 2 minutes and 36 seconds.

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Johnson & Johnson has agreed to a $5.5 billion settlement to resolve tens of thousands of lawsuits alleging that its talc products caused ovarian cancer. The proposed deal, which needs acceptance from 95% of claimants, aims to conclude years of litigation, with payouts starting …

Johnson & Johnson settling talc baby powder lawsuits for $5.5 billion

Johnson & Johnson announced an agreement Monday to pay $5.5 billion to resolve tens of thousands of lawsuits claiming its talc-based baby powder and other talc products caused ovarian cancer, a settlement the company said would bring finality to 15 years of litigation. The …

Johnson & Johnson offers up to $5.5 billion to settle baby powder cancer lawsuits | CNN Business

Johnson & Johnson has proposed a settlement of up to $5.5 billion to resolve approximately 76,000 lawsuits alleging its talcum powder products caused ovarian cancer. The company maintains that the lawsuits lack scientific merit and that its products are safe, despite mixed outcomes in …

Johnson & Johnson offers £4.1bn to settle talcum powder cancer claims

The settlement covers around 76,000 claims that J&J's baby powder caused cancer - Firdous Nazir/NurPhoto Johnson & Johnson (J&J) has agreed to pay an estimated $5.5bn (£4.1bn) to resolve tens of thousands of claims that its baby powder caused ovarian cancer. The pharmaceutical giant's …

Johnson & Johnson reaches $5.5 billion baby powder settlement

View Comments

Johnson & Johnson Proposes to Pay Up to $5.5 Billion to Resolve Remaining Ovarian Cancer Claims

Johnson & Johnson (JNJ) has agreed to commit up to $5.5 billion to settle about 76,000 lawsuits that PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. …

Johnson & Johnson (JNJ) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Johnson & Johnson (JNJ), identifying its major institutional holders like Vanguard, State Street, and BlackRock. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdings. The report …

Why is Johnson & Johnson stock surging today?

Johnson & Johnson Strikes $5.5 Bln Talc Settlement Deal, Subject To 95% Claimant Approval

(RTTNews) - Johnson & Johnson (JNJ) on Monday announced that it has reached an agreement to resolve the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings. The resolution includes a $5.5 billion commitment to …

J&J offers $5.5bn to settle baby powder lawsuits

Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer. The company said the settlement covers around 76,000 claims, having already settled most cases alleging its talc …

Johnson And Johnson Talc Settlement Puts Colgate And Kimberly Clark Stock In Focus

Johnson & Johnson's proposed $5.5 billion talc settlement is impacting investor perceptions of litigation risk and competitive landscape in the baby and personal care market. This article examines how companies like Colgate-Palmolive and Kimberly-Clark, which operate in related spaces, might be affected. It also …

Johnson & Johnson offers $5.5bn to settle talc cancer lawsuits

Johnson & Johnson has proposed a $5.5 billion settlement to resolve tens of thousands of lawsuits in the United States claiming its talc-based baby powder caused ovarian cancer. This agreement covers nearly all outstanding U.S. cases, though J&J continues to deny a link between …

Johnson & Johnson offers to pay $5.5bn to settle baby powder lawsuits

Johnson & Johnson has offered to pay up to $5.5 billion to resolve tens of thousands of lawsuits alleging that its talc-based baby powder causes ovarian cancer. The company denies the allegations, stating that talc is safe and does not cause cancer, and asserts …

Johnson & Johnson to pay up to $5.5B to settle talc lawsuits

Wachiwit/iStock Editorial via Getty Images Johnson & Johnson (JNJ [https://seekingalpha.com/symbol/JNJ]) up 1.4% post-market Monday after saying it agreed to pay up to $5.5B to settle remaining lawsuits [https://seekingalpha.com/pr/20596634-johnson-and-johnson-announces-a-proposed-resolution-of-ovarian-talc-litigation] that alleged its talc products caused ovarian cancer. The company said it reached an agreement for …

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Follows Favorable Multi-District Litigation Court Causation Ruling and the Company's Successful Strategy to Defend Each Case Efficient Conclusion to the Talc Litigation that Eliminates Expense Associated with Litigating Remaining Roughly 76,000 Ovarian Talc Claims NEW BRUNSWICK, N.J., July 27, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: …

Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised …

Johnson & Johnson Immunology Leader Joins Kymera as Chief Medical Officer

Kymera Therapeutics has appointed Terence Rooney, MD, as its new Chief Medical Officer, succeeding Jared Gollob, MD, who will transition to an advisory role. Dr. Rooney, formerly an immunology leader at Johnson & Johnson, will guide Kymera's global clinical development strategy and advance its …

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Kymera Therapeutics, Inc. Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera's industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight years of leadership at the Company WATERTOWN, Mass., July 27, 2026 …

J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?

Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues. In MedTech, J&J is a global leader in electrophysiology, circulatory restoration and heart …

Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck

Quick Read Realty Income (O) yields 5.11% with 670 consecutive monthly dividends, while Verizon (VZ) anchors the group at a 6.46% yield. All five stocks raised dividends through two recessions with cash flow covering each payout, making them viable alternatives to Social Security's 2.8% …

President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling

Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump's financial disclosures released earlier this year. Now a top J&J executive is heading the other direction. The Insider Sale EVP of Global Corporate Affairs Vanessa Broadhurst …

Is Johnson & Johnson Stock a Buy After Its $2 Billion TREMFYA Quarter?

Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson

For Immediate Release Chicago, IL – July 27, 2026 – Today, Zacks Investment Ideas feature highlights General Motors GM, Abbott Laboratories ABT and Johnson & Johnson JNJ. Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher The 2026 Q2 earnings season will continue at …

Johnson & Johnson Now Leads Its Pitch With An Oncology Bet

Johnson & Johnson (JNJ) has shifted its core strategy from broad diversification to a concentrated bet on oncology, aiming to be the number one oncology company by 2030 with over $50 billion in sales. While the company's overall revenue growth remains strong, its net …